These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 23415804)

  • 1. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.
    Lanford RE; Guerra B; Chavez D; Giavedoni L; Hodara VL; Brasky KM; Fosdick A; Frey CR; Zheng J; Wolfgang G; Halcomb RL; Tumas DB
    Gastroenterology; 2013 Jun; 144(7):1508-17, 1517.e1-10. PubMed ID: 23415804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells.
    Li L; Barry V; Daffis S; Niu C; Huntzicker E; French DM; Mikaelian I; Lanford RE; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):912-921. PubMed ID: 29247724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.
    Boni C; Vecchi A; Rossi M; Laccabue D; Giuberti T; Alfieri A; Lampertico P; Grossi G; Facchetti F; Brunetto MR; Coco B; Cavallone D; Mangia A; Santoro R; Piazzolla V; Lau A; Gaggar A; Subramanian GM; Ferrari C
    Gastroenterology; 2018 May; 154(6):1764-1777.e7. PubMed ID: 29378197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B.
    Menne S; Tumas DB; Liu KH; Thampi L; AlDeghaither D; Baldwin BH; Bellezza CA; Cote PJ; Zheng J; Halcomb R; Fosdick A; Fletcher SP; Daffis S; Li L; Yue P; Wolfgang GH; Tennant BC
    J Hepatol; 2015 Jun; 62(6):1237-45. PubMed ID: 25559326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating the innate immune response to counter chronic hepatitis B virus infection.
    Lamb C; Arbuthnot P
    Expert Opin Biol Ther; 2016 Dec; 16(12):1517-1527. PubMed ID: 27603796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.
    Janssen HLA; Brunetto MR; Kim YJ; Ferrari C; Massetto B; Nguyen AH; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Yoshida EM; Ahn SH; Tsai NCS; Fung S; Gane EJ
    J Hepatol; 2018 Mar; 68(3):431-440. PubMed ID: 29104121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B.
    Zoulim F; Luangsay S; Durantel D
    Gastroenterology; 2013 Jun; 144(7):1342-4. PubMed ID: 23710602
    [No Abstract]   [Full Text] [Related]  

  • 9. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
    Gane EJ; Lim YS; Gordon SC; Visvanathan K; Sicard E; Fedorak RN; Roberts S; Massetto B; Ye Z; Pflanz S; Garrison KL; Gaggar A; Mani Subramanian G; McHutchison JG; Kottilil S; Freilich B; Coffin CS; Cheng W; Kim YJ
    J Hepatol; 2015 Aug; 63(2):320-8. PubMed ID: 25733157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
    Lawitz E; Gruener D; Marbury T; Hill J; Webster L; Hassman D; Nguyen AH; Pflanz S; Mogalian E; Gaggar A; Massetto B; Subramanian GM; McHutchison JG; Jacobson IM; Freilich B; Rodriguez-Torres M
    Antivir Ther; 2015; 20(7):699-708. PubMed ID: 25105516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses.
    Fosdick A; Zheng J; Pflanz S; Frey CR; Hesselgesser J; Halcomb RL; Wolfgang G; Tumas DB
    J Pharmacol Exp Ther; 2014 Jan; 348(1):96-105. PubMed ID: 24133297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
    Boni C; Janssen HLA; Rossi M; Yoon SK; Vecchi A; Barili V; Yoshida EM; Trinh H; Rodell TC; Laccabue D; Alfieri A; Brillo F; Fisicaro P; Acerbi G; Pedrazzi G; Andreone P; Cursaro C; Margotti M; Santoro R; Piazzolla V; Brunetto MR; Coco B; Cavallone D; Zhao Y; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Massetto B; Fung S; Ahn SH; Ma X; Mangia A; Ferrari C
    Gastroenterology; 2019 Jul; 157(1):227-241.e7. PubMed ID: 30930022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
    Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line.
    Das D; Sengupta I; Sarkar N; Pal A; Saha D; Bandopadhyay M; Das C; Narayan J; Singh SP; Chakrabarti S; Chakravarty R
    BMC Infect Dis; 2017 Jan; 17(1):76. PubMed ID: 28088184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B.
    Daffis S; Balsitis S; Chamberlain J; Zheng J; Santos R; Rowe W; Ramakrishnan D; Pattabiraman D; Spurlock S; Chu R; Kang D; Mish M; Ramirez R; Li L; Li B; Ma S; Hung M; Voitenleitner C; Yon C; Suresh M; Menne S; Cote P; Delaney WE; Mackman R; Fletcher SP
    Hepatology; 2021 Jan; 73(1):53-67. PubMed ID: 32246499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment.
    Agarwal K; Ahn SH; Elkhashab M; Lau AH; Gaggar A; Bulusu A; Tian X; Cathcart AL; Woo J; Subramanian GM; Andreone P; Kim HJ; Chuang WL; Nguyen MH
    J Viral Hepat; 2018 Nov; 25(11):1331-1340. PubMed ID: 29851204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist.
    Lopatin U; Wolfgang G; Tumas D; Frey CR; Ohmstede C; Hesselgesser J; Kearney B; Moorehead L; Subramanian GM; McHutchison JG
    Antivir Ther; 2013; 18(3):409-18. PubMed ID: 23416308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model.
    Wu J; Huang S; Zhao X; Chen M; Lin Y; Xia Y; Sun C; Yang X; Wang J; Guo Y; Song J; Zhang E; Wang B; Zheng X; Schlaak JF; Lu M; Yang D
    J Virol; 2014 Sep; 88(18):10421-31. PubMed ID: 24920792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel orally available small molecule that inhibits hepatitis B virus expression.
    Mueller H; Wildum S; Luangsay S; Walther J; Lopez A; Tropberger P; Ottaviani G; Lu W; Parrott NJ; Zhang JD; Schmucki R; Racek T; Hoflack JC; Kueng E; Point F; Zhou X; Steiner G; Lütgehetmann M; Rapp G; Volz T; Dandri M; Yang S; Young JAT; Javanbakht H
    J Hepatol; 2018 Mar; 68(3):412-420. PubMed ID: 29079285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.
    Amin OE; Colbeck EJ; Daffis S; Khan S; Ramakrishnan D; Pattabiraman D; Chu R; Micolochick Steuer H; Lehar S; Peiser L; Palazzo A; Frey C; Davies J; Javanbakht H; Rosenberg WMC; Fletcher SP; Maini MK; Pallett LJ
    Hepatology; 2021 Jul; 74(1):55-71. PubMed ID: 33368377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.